1
2024 NAMS Menopause Certification
Exam – Real Questions with Correct
Detailed Answers (Verified 2024–2025
Edition)
Question 1
What is the definition of the climacteric phase?
a) The final menstrual period (FMP)
b) The period of endocrinologic, somatic, and psychologic changes around menopause
c) The cessation of ovulation before age 40
d) The stabilization of hormone levels post-menopause
Correct Answer: b) The period of endocrinologic, somatic, and psychologic changes around
menopause
Rationale: The climacteric phase encompasses the transition from reproductive to non-
reproductive years, involving hormonal, physical, and psychological changes. The FMP (a)
defines menopause, cessation of ovulation before age 40 (c) is primary ovarian insufficiency, and
hormone stabilization (d) occurs in late post-menopause.
Question 2
Which stage of the STRAW+10 criteria is characterized by a persistent difference of 7 or more
days in consecutive cycle length?
a) Late menopause transition
b) Early menopause transition
c) Early post-menopause
d) Late post-menopause
Correct Answer: b) Early menopause transition
Rationale: The STRAW+10 staging system defines the early menopause transition (stage -2) by
a persistent difference of ≥7 days in menstrual cycle length, reflecting follicular aging and
hormonal variability. Late menopause transition (a) involves ≥60 days of amenorrhea, and post-
menopause stages (c, d) occur after the FMP.
, 2
Question 3
Which symptom is classified as a vasomotor symptom (VMS) of menopause?
a) Dyspareunia
b) Hot flashes
c) Mood changes
d) Vaginal dryness
Correct Answer: b) Hot flashes
Rationale: Vasomotor symptoms include hot flashes and night sweats, caused by
thermoregulatory dysfunction. Dyspareunia (a) and vaginal dryness (d) are genitourinary
symptoms, while mood changes (c) are psychological symptoms of menopause.
Question 4
Which nonpharmacologic treatment is highly recommended by NAMS for managing vasomotor
symptoms?
a) Acupuncture
b) Cognitive behavioral therapy (CBT)
c) Dietary supplements
d) Herbal remedies
Correct Answer: b) Cognitive behavioral therapy (CBT)
Rationale: NAMS recommends CBT and clinical hypnosis as evidence-based nonpharmacologic
treatments for VMS due to their efficacy in reducing symptom severity. Acupuncture (a) has
limited evidence, and dietary supplements (c) and herbal remedies (d) lack consistent data for
VMS management.
Question 5
A 52-year-old woman with a uterus is prescribed hormone therapy (HT) for severe hot flashes.
What is the appropriate regimen?
a) Estrogen alone
b) Progestin alone
c) Estrogen plus progestin
d) Testosterone alone
Correct Answer: c) Estrogen plus progestin
Rationale: Women with a uterus require estrogen plus progestin to prevent endometrial
hyperplasia from unopposed estrogen. Estrogen alone (a) is for women without a uterus,
progestin alone (b) is not standard for VMS, and testosterone (d) is not indicated for hot f lashes.
, 3
Question 6
What is a key advantage of transdermal estrogen over oral estrogen?
a) Increased libido
b) Lower risk of venous thromboembolism (VTE)
c) Improved triglyceride levels
d) Reduced menopausal symptoms
Correct Answer: b) Lower risk of venous thromboembolism (VTE)
Rationale: Transdermal estrogen bypasses first-pass liver metabolism, reducing VTE risk
compared to oral estrogen. It has no impact on libido (a), does not increase triglycerides (c), and
both forms reduce menopausal symptoms (d) equally.
Question 7
According to NAMS, when is it considered safe to initiate menopausal hormone therapy (MHT)?
a) In women over 65 years old
b) In women within 10 years of menopause or under 60 years old
c) In women with a history of breast cancer
d) In women with active liver disease
Correct Answer: b) In women within 10 years of menopause or under 60 years old
Rationale: NAMS states MHT is likely safe for women within 10 years of menopause or under
60 with no contraindications, as benefits outweigh risks in this group. It is not recommended
over 65 for primary prevention (a), or in women with breast cancer (c) or active liver disease (d).
Question 8
What is the first-line treatment for severe vasomotor symptoms after nonpharmacologic options?
a) Selective serotonin reuptake inhibitors (SSRIs)
b) Systemic hormone therapy
c) Gabapentin
d) Clonidine
Correct Answer: b) Systemic hormone therapy
Rationale: Systemic hormone therapy (HT) is the most effective treatment for severe VMS,
providing optimal relief for hot flashes and night sweats. SSRIs (a), gabapentin (c), and clonidine
(d) are alternatives but less effective.
2024 NAMS Menopause Certification
Exam – Real Questions with Correct
Detailed Answers (Verified 2024–2025
Edition)
Question 1
What is the definition of the climacteric phase?
a) The final menstrual period (FMP)
b) The period of endocrinologic, somatic, and psychologic changes around menopause
c) The cessation of ovulation before age 40
d) The stabilization of hormone levels post-menopause
Correct Answer: b) The period of endocrinologic, somatic, and psychologic changes around
menopause
Rationale: The climacteric phase encompasses the transition from reproductive to non-
reproductive years, involving hormonal, physical, and psychological changes. The FMP (a)
defines menopause, cessation of ovulation before age 40 (c) is primary ovarian insufficiency, and
hormone stabilization (d) occurs in late post-menopause.
Question 2
Which stage of the STRAW+10 criteria is characterized by a persistent difference of 7 or more
days in consecutive cycle length?
a) Late menopause transition
b) Early menopause transition
c) Early post-menopause
d) Late post-menopause
Correct Answer: b) Early menopause transition
Rationale: The STRAW+10 staging system defines the early menopause transition (stage -2) by
a persistent difference of ≥7 days in menstrual cycle length, reflecting follicular aging and
hormonal variability. Late menopause transition (a) involves ≥60 days of amenorrhea, and post-
menopause stages (c, d) occur after the FMP.
, 2
Question 3
Which symptom is classified as a vasomotor symptom (VMS) of menopause?
a) Dyspareunia
b) Hot flashes
c) Mood changes
d) Vaginal dryness
Correct Answer: b) Hot flashes
Rationale: Vasomotor symptoms include hot flashes and night sweats, caused by
thermoregulatory dysfunction. Dyspareunia (a) and vaginal dryness (d) are genitourinary
symptoms, while mood changes (c) are psychological symptoms of menopause.
Question 4
Which nonpharmacologic treatment is highly recommended by NAMS for managing vasomotor
symptoms?
a) Acupuncture
b) Cognitive behavioral therapy (CBT)
c) Dietary supplements
d) Herbal remedies
Correct Answer: b) Cognitive behavioral therapy (CBT)
Rationale: NAMS recommends CBT and clinical hypnosis as evidence-based nonpharmacologic
treatments for VMS due to their efficacy in reducing symptom severity. Acupuncture (a) has
limited evidence, and dietary supplements (c) and herbal remedies (d) lack consistent data for
VMS management.
Question 5
A 52-year-old woman with a uterus is prescribed hormone therapy (HT) for severe hot flashes.
What is the appropriate regimen?
a) Estrogen alone
b) Progestin alone
c) Estrogen plus progestin
d) Testosterone alone
Correct Answer: c) Estrogen plus progestin
Rationale: Women with a uterus require estrogen plus progestin to prevent endometrial
hyperplasia from unopposed estrogen. Estrogen alone (a) is for women without a uterus,
progestin alone (b) is not standard for VMS, and testosterone (d) is not indicated for hot f lashes.
, 3
Question 6
What is a key advantage of transdermal estrogen over oral estrogen?
a) Increased libido
b) Lower risk of venous thromboembolism (VTE)
c) Improved triglyceride levels
d) Reduced menopausal symptoms
Correct Answer: b) Lower risk of venous thromboembolism (VTE)
Rationale: Transdermal estrogen bypasses first-pass liver metabolism, reducing VTE risk
compared to oral estrogen. It has no impact on libido (a), does not increase triglycerides (c), and
both forms reduce menopausal symptoms (d) equally.
Question 7
According to NAMS, when is it considered safe to initiate menopausal hormone therapy (MHT)?
a) In women over 65 years old
b) In women within 10 years of menopause or under 60 years old
c) In women with a history of breast cancer
d) In women with active liver disease
Correct Answer: b) In women within 10 years of menopause or under 60 years old
Rationale: NAMS states MHT is likely safe for women within 10 years of menopause or under
60 with no contraindications, as benefits outweigh risks in this group. It is not recommended
over 65 for primary prevention (a), or in women with breast cancer (c) or active liver disease (d).
Question 8
What is the first-line treatment for severe vasomotor symptoms after nonpharmacologic options?
a) Selective serotonin reuptake inhibitors (SSRIs)
b) Systemic hormone therapy
c) Gabapentin
d) Clonidine
Correct Answer: b) Systemic hormone therapy
Rationale: Systemic hormone therapy (HT) is the most effective treatment for severe VMS,
providing optimal relief for hot flashes and night sweats. SSRIs (a), gabapentin (c), and clonidine
(d) are alternatives but less effective.
